Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small-molecule BCL-2 inhibitor; bortezomib can indirectly inhibit MCL-1. In preclinical studies, venetoclax enhanced bortezomib ac...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2017-11, Vol.130 (22), p.2392-2400
Main Authors: Moreau, Philippe, Chanan-Khan, Asher, Roberts, Andrew W., Agarwal, Amit B., Facon, Thierry, Kumar, Shaji, Touzeau, Cyrille, Punnoose, Elizabeth A., Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia, Salem, Ahmed Hamed, Freise, Kevin J., Leverson, Joel D., Enschede, Sari Heitner, Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Harrison, Simon J.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bortezomib - administration & dosage
Bortezomib - adverse effects
Bortezomib - therapeutic use
Bridged Bicyclo Compounds, Heterocyclic - administration & dosage
Bridged Bicyclo Compounds, Heterocyclic - adverse effects
Bridged Bicyclo Compounds, Heterocyclic - therapeutic use
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Dexamethasone - therapeutic use
Female
Humans
Male
Middle Aged
Multiple Myeloma - drug therapy
Neoplasm Recurrence, Local - drug therapy
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!